Clinical trials: Adalimumab
Immune System Disorder
Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects
This healthy male volunteers study will evaluate 148 subjects who will receive a single sub-cutaneous dose of HLX03 （a monoclonal antibody against TNF-a, 40 mg/ 0.8 mL） or Adalimumab(Humira,China spourced,40 mg/0.8 mL injection…
- Trial name
- NCT03357939
- Testing
- HLX03, adalimumab
- Where
- China
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients
One of the main potential causes of these failures of BP therapy response is the development of Anti-drug Anti-body (ADAb) in some patients.
- Trial name
- ABI-RA (NCT02116504)
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
The purpose of this study is to evaluate the efficacy and safety of namilumab in combination with existing methotrexate (MTX) therapy over 24 weeks in participants with moderate to severe early rheumatoid arthritis (RA)…
- Trial name
- TELLUS (NCT02393378)
- Testing
- Namilumab, Adalimumab, Methotrexate
- Where
- 13 sites in Czechia, Estonia and 3 more
- Volunteers
- 7 people
- Sponsor
- Takeda
Crohn's Disease
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
The purpose of this study is to evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in participants with Crohn's disease.
- Trial name
- NCT02185014
- Testing
- Adalimumab
- Volunteers
- 252 people
- Sponsor
- AbbVie
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation
Psoriatic Arthritis
Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine
Safety and effectiveness, quality of life and work productivity of Humira in patients with psoriatic arthritis in clinical routine.
- Trial name
- ELAN (NCT01078610)
- Testing
- adalimumab (Humira)
- Sponsor
- Abbott
Arthritis; Behcet
Efficacy of Humira in Behcet Patients With Arthritis
Hypothesis - Behcet's disease is a multisystemic chronic relapsing inflammatory disease, classified among the vasculitides. The clinical manifestations include mucocutaneous lesions, articular, ocular, vascular, gastrointestinal…
- Trial name
- NCT01497717
- Testing
- Adalimumab (Humira)
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Rambam Health Care Campus
Psoriasis
Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis
Vitamins modulating homocysteine affect both TNF-alpha, vascular endothelial growth factor, and theoretically enhance the anti-inflammatory version of NOS thus hopefully increasing the efficacy and reducing the chance of some…
- Trial name
- NCT01704599
- Testing
- Humira Then Humira plus 3 B vitamins
- Volunteers
- 8 people
- Sponsor
- Wayne State University
Psoriasis Vulgaris
Dose Tapering Study of Adalimumab in Psoriasis
The optimal therapeutic serum trough level (Ctrough) of adalimumab was defined between 3,5 and 7,0 µg/ml in patients with plaque type psoriasis. An adalimumab Ctrough above this therapeutic range did not add clinical response.
- Trial name
- NCT04028713
- Testing
- Venapuncture, Dried blood spot, Dose reduction
- Where
- 7 sites in Belgium
- Volunteers
- 19 people
- Sponsor
- University Hospital, Ghent
Ankylosing Spondylitis (AS), Psoriasis
Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases
The objective of this study is to evaluate the effect of adalimumab on health outcomes in participants with rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis.
- Conditions
- Ankylosing Spondylitis (AS), Psoriasis, Rheumatoid Arthritis (RA)
- Trial name
- ADMIT (NCT03339089)
- Where
- 10 sites in China
- Volunteers
- 224 people
- Sponsor
- AbbVie
Ulcerative Colitis, Thromboembolism
Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events
Post-authorization, prospective and unicenter clinical trial, in which patients with UC will be included. The treatment with anti-TNFα (infliximab, adalimumab or golimumab) or JAK-inhibitors (tofacitinib) will be initiated by…
- Trial name
- NCT05313620
- Testing
- Tofacitinib, Infliximab Adalimumab y Golimumab
- Where
- Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Rheumatoid Arthritis (RA)
Optimization of Treatment With Adalimumab (Humira)
The purpose of this trial is to assess the effect of two Intensive Outpatient Management Strategies (IOMS) versus Routine Care (RC) on the outcomes of patients with Rheumatoid Arthritis (RA) that are treated with adalimumab.
- Trial name
- NCT01585064
- Testing
- DAS28-IOMS, 0SJ-IOMS, Routine Care (RC)
- Where
- Canada
- Volunteers
- 309 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Chronic Plaque Psoriasis
Chronic Plaque Psoriasis (Ps) Registry
The purpose of this study is to evaluate the long-term safety of Humira® in Adult Patients with Chronic Plaque Psoriasis (Ps).
- Trial name
- NCT00799877
- Where
- 339 sites in United States, Austria and 12 more
- Volunteers
- 6,065 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Pain Management in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Patients Who Are About to be Treated With Adalimumab
The purpose of this study is to assess whether or not adalimumab (Humira®) can influence pain medication in participants with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) with or without…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- NCT01273519
- Where
- 15 sites in Austria
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
Non-infectious Intermediate Posterior- or Pan-uveitis
A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis
Non-infectious intermediate-, posterior- and pan-uveitis (NIIPPU) are sight threatening diseases with a high patient burden and negative impact on quality of life.
- Trial name
- NCT05414201
- Testing
- Adalimumab
- Where
- 7 sites in China
- Volunteers
- 87 people
- Sponsor
- AbbVie
Psoriasis
A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of CNTO 1959 in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- X-PLORE (NCT01483599)
- Testing
- CNTO 1959 (5 mg), CNTO 1959 (15 mg), CNTO 1959 (50 mg)
- Where
- 40 sites in United States, Belgium and 3 more
- Volunteers
- 293 people
- Sponsor
- Janssen Inc.
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
This study aims to systematically evaluate the safety and efficacy of adalimumab combined with paclitaxel, carboplatin, and short-course radiotherapy in the neoadjuvant treatment of esophageal squamous cell carcinoma.
- Trial name
- ANCRE (NCT07595770)
- Testing
- • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Plaque Psoriasis
Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients
Psoriasis vulgaris is associated with significant comorbidity including depression, increased risk of cardiovascular events, diminished quality of life, as well as overall increased mortality.
- Trial name
- NCT06370156
- Testing
- Adalimumab
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
The purpose of the study is to collect preliminary data on whether the drug adalimumab (also called Humira) can decrease pain and stiffness, improve quality of life, and is safe in people with mucopolysaccharidosis type I, II, or…
- Conditions
- Mucopolysaccharidosis Type I, Mucopolysaccharidosis Type II, Mucopolysaccharidosis Type VI
- Trial name
- NCT02437253
- Testing
- Adalimumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Psoriasis
Primary UVB-311nm and Adalimumab in Psoriasis Patients
Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis.
- Trial name
- NCT00638261
- Testing
- UVB-311nm
- Where
- Austria
- Volunteers
- 4 people
- Sponsor
- Medical University of Graz